SLXN
Income statement / Annual
Last year (2023), Silexion Therapeutics LTD's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Silexion Therapeutics LTD's net income was -$4.94 M.
See Silexion Therapeutics LTD,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
Period Ended |
12/31/2023 |
12/31/2022 |
Operating Revenue |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
Research and Development Expenses |
$3.71 M
|
$3.23 M
|
General & Administrative Expenses |
$928,000.00
|
$577,000.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$928,000.00
|
$577,000.00
|
Other Expenses |
$45,000.00
|
$57,000.00
|
Operating Expenses |
$4.68 M
|
$3.86 M
|
Cost And Expenses |
$4.68 M
|
$3.86 M
|
Interest Income |
$153,000.00
|
$114,000.00
|
Interest Expense |
$9,000.00
|
$85,000.00
|
Depreciation & Amortization |
$45,000.00
|
$57,000.00
|
EBITDA |
-$4.64 M |
-$3.80 M |
EBITDA Ratio |
0
|
0
|
Operating Income Ratio |
0
|
0
|
Total Other Income/Expenses Net |
-$395,000.00
|
$396,000.00
|
Income Before Tax |
-$5.08 M
|
-$3.46 M
|
Income Before Tax Ratio |
0
|
0
|
Income Tax Expense |
$32,000.00
|
$24,000.00
|
Net Income |
-$4.94 M
|
-$3.22 M
|
Net Income Ratio |
0
|
0
|
EPS |
-0.61 |
-0.39 |
EPS Diluted |
-0.61 |
-0.39 |
Weighted Average Shares Out |
$8.15 M
|
$8.15 M
|
Weighted Average Shares Out Diluted |
$8.15 M
|
$8.15 M
|
Link |
|
|